Johnson & Johnson Q2 Earnings Call Highlights

1 month ago 9

MarketBeat

Wed, July 15, 2026 astatine 9:04 AM CDT 8 min read

Key Points

Interested successful Johnson & Johnson? Here are 5 stocks we similar better.
Johnson & Johnson raised its full-year 2026 outlook aft reporting a Q2 bushed connected some gross and earnings, with worldwide income of $25.3 cardinal and adjusted EPS of $2.90. Management said maturation was driven by Innovative Medicine and caller merchandise launches, helping offset continued STELARA biosimilar pressure.
Innovative Medicine was the main maturation engine, with beardown performances from oncology drugs similar DARZALEX, CARVYKTI, TECVAYLI and TALVEY, positive large momentum from TREMFYA and newer launches specified arsenic ICOTYDE and INLEXZO. TREMFYA deed its archetypal $2 cardinal quarter, portion STELARA income fell sharply.
MedTech grew much slowly, peculiarly successful cardiovascular, wherever electrophysiology and Abiomed weighed connected results, though surgery, imaginativeness and orthopedics each accelerated. Despite that mixed performance, J&J said it remains connected way for astir $21 billion successful full-year escaped currency travel and continues to spot pipeline and motorboat catalysts ahead.

This Dividend ETF Choice Could Shape Your Income Strategy Through 2026

Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook aft reporting second-quarter income maturation that absorption said was supported by spot successful Innovative Medicine, caller merchandise launches and a wide portfolio that helped offset continued unit from STELARA biosimilar competition.

Chairman and Chief Executive Officer Joaquin Duato said the institution delivered a "Q2 bushed connected the apical and bottommost enactment and raised guidance," describing 2026 arsenic a twelvemonth of accelerated maturation for Johnson & Johnson. The institution reported worldwide quarterly income of $25.3 billion, up 5.6% operationally. Excluding STELARA, Duato said Johnson & Johnson grew treble digits successful the quarter.

→ The SK Hynix IPO and 2027's AI Memory Squeeze

3 Stocks Doing the Heavy Lifting successful Healthcare's Rebound

Ryan Kurz, Vice President of Investor Relations, said U.S. income roseate 7.3%, portion income extracurricular the U.S. accrued 3.4%. Net net were $5.5 billion, and diluted net per stock were $2.27, compared with $2.29 a twelvemonth earlier. Adjusted nett net were $7.1 billion, with adjusted diluted EPS of $2.90, up 4.7% from the 2nd 4th of 2025.

Innovative Medicine Leads Growth

Innovative Medicine income totaled $16.4 billion, up 6.8% operationally, contempt what Kurz described arsenic an astir 760-basis-point headwind from STELARA. The part posted 8.9% maturation successful the U.S. and 3.6% maturation extracurricular the U.S.

→ 3 Space Stocks That Could Outshine SpaceX After Its IPO

Read Entire Article